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It is now more than 30 years since the first adjuvant
chemotherapy trials were initiated, and several important
conclusions can clearly be drawn from these studies. When
the first adjuvant trials were begun, the proposition that
patients with apparently early breast cancer actually had well
established, distant metastases at the time of diagnosis was
still controversial. By demonstrating that chemotherapy can
prolong the time to the appearance of recurrent disease, these
studies validated the rationale for the trials and, at the same
time, provided new hope for more effectively treating breast
cancer. Although improvements in disease-free survival have
not always led to similar improvements in overall survival,
three separate studies have now demonstrated that the sur-
vival of premenopausal women (or women less than 50 years
old) can be significantly improved by the use of adjuvant
chemotherapy (Fisher et al., 1986; Bonadonna et al., 1989;
Brincker et al., 1987), and an overview combining the results
of all trials, worldwide, has demonstrated that the odds of
death in the first 5 years following diagnosis can be reduced
by 22 ± 6% for women in this age group (Early Breast
Cancer Trialists Collaborative Group, 1988). The failure of
chemotherapy to improve similarly the survival of older
women cannot be fully explained, since adjuvant chemo-
therapy prolongs the time to recurrence in women of all ages.
However, the overview analysis establishes quite convincingly
that the effects ofchemotherapy in younger and older women
are at least quantitatively different (Early Breast Cancer
Trialists Collaborative Group, 1988), and the possibility that
these differences are to some extent qualitative, as well, can-
not yet be ruled out (Brincker et al., 1987).
Although the implications ofthese results are monumental,
the size and nature of the benefits from the use of currently
available therapies fall short of early promise (Holland et al.,
1976). The results of the very large number of different trials
are often contradictory, which is why combining the data in
overviews or metaanalyses is particularly helpful. As the size
of individual trials grow larger, it is increasingly easy to
detect very small but statistically significant effects of
therapy, and this 'inflation of the P value' is further exacer-
bated by the overview process. Faced with a similar dilemma
in other settings, the clinician might judge for himself by
evaluating the results and side effects of therapy in his own
practice, but this is not so easy in the assessment of adjuvant
chemotherapy because the side-effects, which can be con-
siderable, are immediate and mostly readily apparent. The
benefits from therapy, if any, are delayed and never really
evident in any individual patient. For this reason the trial
data must be carefully scrutinised to determine how large the
benefits really are, which patients derive enough benefit to
justify the cost, and what kind of benefits accrue: a prolonga-
tion of time to recurrence, a prolongation ofsurvival short of
cure, or eradication of the disease and a return to the life
expectancy the patient might have had if she had not had
breast cancer.
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Although most of the data on the use of combination
chemotherapy regimens for periods in excess of a few days
were derived from studies that enrolled primarily or exclu-
sively patients with histologically involved lymph nodes
('node positive patients'), there are now almost a dozen
published studies on the effects of chemotherapy in node
negative patients (Henderson et al., 1990), including the
reports from the West Midlands group that appeared
recently (Morrison et al., 1989a, b). Three of these studies
appeared in a single issue of the New England Journal of
Medicine (Fisher et al., 1989; Mansour et al., 1989; Ludwig
Breast Cancer Study Group, 1989) accompanied by three
editorials (Relman et al., 1989; DeVita, 1989; McGuire, 1989)
and heralded 10 months earlier by a 'clinical alert' sent out
from the National Cancer Institute (USA) to all American
oncologists (NCI, 1988). The results of the West Midlands
trial in node negative patients differ from most of the other
trials in their failure to demonstrate at least a transient
improvement in the disease-free survival of the treated
patients. However, these results are similar to most other
node negative studies in their failure to show a statistically
significant improvement in overall survival, and the West
Midlands trial is particularly important in this regard
because the median follow-up is longer than in any other
trial except the Swiss OSAKO trial 06/74 (Senn et al., 1989).
Those who are uncomfortable with these seeming contra-
dictions in trial outcomes may wish to dismiss the West
Midlands study because it utilised chlorambucil rather than
the more conventional cyclophosphamide or because the
local recurrence rates were so high in this study. An equally
plausible explanation for the lack of chemotherapy effect in
this study is chance alone. If the effects of adjuvant chemo-
therapy are really quite small, then they might appear to be
particularly large in some studies, such as the Milan IV trial
with a total of 90 patients (Bonadonna et al., 1987), and
equally unimpressive in other studies. Although we might
anticipate that the benefits of adjuvant chemotherapy will be
the same in the node negative patients who will eventually
recur as in node positive patients, almost all of whom will
eventually die of their breast cancer (Rosen et al., 1989), the
number of node negative patients cured by local therapy
alone will be substantially larger, and these cured patients
who cannot possibly benefit from adjuvant chemotherapy
will dilute the effects of therapy. Thus, although the propor-
tional reduction in recurrence rate or mortality will likely be
the same among node negative and node positive patients,
the absolute reductions may be substantially smaller and not
reliably evaluated in any but the largest studies (Gelber et al.,
1986). If absolute survival advantages do prove to be quite
small, or even non-existent, among all treated node negative
patients, delayed toxicities, such as second tumours, may
eventually outweigh these benefits. The recent demonstration
that adjuvant tamoxifen therapy, a particularly non-toxic
option, may be followed by an increased incidence of endo-
metrial carcinoma (Fornander et al., 1989) or that adjuvant
radiotherapy may result in an increased incidence of second
tumours and heart disease among patients with the best
prognosis (Haybittle et al., 1989) should lead to caution in
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the use of adjuvant chemotherapy among node negative
patients, 50-75% of whom will experience these late side-
effects even though they could not possibly benefit from the
therapy because they had no distant metastases.
Among premenopausal, node positive patients the question
is not whether to treat but which regimens to use. It has been
shown in many individual studies and in the overview that
combinations of drugs are marginally more effective than
single agents, and there is no evidence that treatment courses
in excess of 4-6 months offer a survival advantage over
shorter courses (Early Breast Cancer Trialists Collaborative
Group, 1988). The regimens most extensively evaluated have
utilised a combination of cyclophosphamide, methotrexate
and 5-fluorouracil (CMF) with or without other drugs such
as prednisone and vincristine, and no other combination has
yet been shown to be more effective (Early Breast Cancer
Trialists Collaborative Group, 1988). The second West Mid-
lands trial (Morrison et al., 1989b) evaluated the combination
of CMF plus doxorubicin and vincristine (AVCMF). This is
the only study in which patients have been randomised to
either a doxorubicin combination or no adjuvant therapy at
all, and the improvement in relapse-free survival as a result
of treatment is entirely consistent with that seen in studies of
adjuvant CMF. Although a doxorubicin combination has
been compared to a non-doxorubicin regimen in several
studies (Fisher et al., 1989; Mathe et al., 1987), only one has
compared a doxorubicin combination with CMF (Mathe et
al., 1987). In that trial the survival of premenopausal, but
not post-menopausal, women was improved by the use of
AVCF, but several variables beside the addition of doxo-
rubicin were changed in the AVCF arm. The failure to see an
overall survival benefit in this trial from the West Midlands
does not obviate the firm evidence from other trials and the
overview that adjuvant chemotherapy can prolong the sur-
vival of younger women. Taken together, the data from
adjuvant chemotherapy trials which include a doxorubicin
combination suggest that these combinations may be superior
to CMF, but the evidence is still inadequate to justify the use
of such combinations in routine practice, especially since
doxorubicin is often more toxic and may be associated with
an increased incidence of congestive heart failure years after
completion of treatment.
The investigators from the West Midlands have presented
their data as a difference in median disease-free or overall
survival between treated and control patients. This method
has several advantages. First, it more accurately reflects the
biological effect of therapy. There is no evidence for a
plateau in the survival curves of treated patients in any of the
adjuvant studies and thus no reason to assume that adjuvant
chemotherapy cures any patient who would not be cured by
local therapy alone. It is more likely that the effects of
therapy are transient and, based on our experience in
patients with metastatic disease where we can more readily
measure tumour shrinkage, that tumour cell destruction by
chemotherapy varies considerably from one patient to
another (Henderson, 1987). A 10% difference in relapse-free
or overall survival at a single point in time should not lead to
the conclusion that only 10% of the patients have benefited.
Exactly the same difference on a survival curve can result
from a variable but transient improvement in the survival of
every treated patient. The calculated difference in median
disease-free or overall survival is one method of averaging
this variable benefit. Not only is this figure a more accurate
expression of the transient effect of therapy on survival, it
also permits patient and physician to calculate quickly the
net prolongation of time to recurrence or prolongation of
survival by subtracting the time the patient was receiving
therapy and most likely had a lower quality of life because of
the toxicities of treatment. For example, in the West
Midlands trials the median relapse-free survival of pre-
menopausal women was prolonged by 17 months. After sub-
traction of the 6 months in which adjuvant chemotherapy
was administered, the net increase in time to recurrence is
still 12 months. Many (but certainly not all) patients and
physicians would consider this a worthwhile result of treat-
ment even if a survival advantage does not eventuate. In
contrast, the prolongation in the median relapse-free survival
for post-menopausal women was only 8 months and the net
increase in quality life only 2 months. The fact that this
benefit approaches statistical significance does not outweigh
the fact that it is a lot of fuss and bother for very little net
gain.
While the results of the first generation of adjuvant
chemotherapy trials are disappointingly small and insufficient
to recommend this therapy for routine use in any group
except premenopausal, node positive patients, these trial
results provide a strong impetus for further study. One of the
most pressing issues is the difference in the effect of therapy
in premenopausal and postmenopausal women. Since we
know that adjuvant chemotherapy can substantially prolong
the time to recurrence in both groups of women and that
chemotherapy is effective in shrinking measurable metastases
in both premenopausal and post-menopausal women, it is
difficult to ascribe all the benefits of adjuvant therapy in
premenopausal women to its effect on ovarian function. On
the other hand, the demonstration that adjuvant tamoxifen
substantially prolongs both the disease-free and overall sur-
vival of post-menopausal women (Smith, 1988) has forced
many of us, including this author, to recognise how very
effective endocrine therapy really is in the treatment of breast
cancer. Presumably adjuvant tamoxifen is more effective than
adjuvant chemotherapy in post-menopausal women, but ran-
domised trials directly comparing endocrine therapy alone
with chemotherapy alone have not yet been completed in
either premenopausal or post-menopausal women. I suspect
we will eventually find that chemotherapy is only modestly
more effective than oophorectomy, radiation induced ovarian
ablation, or LHRH analogues as systemic adjuvant treat-
ment. In fact, it may take a very large trial to demonstrate
differences between these two modalities. However, it is not
clear how the benefits of adjuvant endocrine therapy can be
increased, since there seems to be only a limited population
of tumour cells that are affected by this treatment. (Although
the data from several trials suggest that some small per-
centage of patients with oestrogen receptor negative tumours
may benefit from adjuvant tamoxifen treatment (Smith,
1988), these trial results should not lead to the conclusion
that our understanding of the interaction between endocrine
therapy and hormone receptors, which are present on only a
limited portion of tumour cells in any patient, is fundamen-
tally incorrect.) Because of these limitations in the use of
endocrine therapy, further studies on the use of
chemotherapy should not be prematurely abandoned. How-
ever, it seems unlikely that minor alterations in the schedul-
ing of chemotherapy or the addition of one more drug
among those available will substantially alter the results
obtained to date. Bold, new approaches are necessary. In
North America much of this effort is now directed towards
increasing drug dose, and this may prove to be a reasonable
strategy, especially among patients with rapidly growing
disease. However, most breast cancer patients die 5 years or
more after their original diagnosis, presumably of the more
indolent varieties of the disease. Equal emphasis needs to be
placed on strategies for the treatment of this group of
patients, and possibly this is a fertile area for the study of
biological response modifiers, anti-growth factors or growth
inhibitors, and methods of blocking receptors to growth
factors.
The debate on whether adjuvant chemotherapy works
should now be put aside. The demonstration that patients
have well established micrometastases at the time of diag-
nosis and that these micrometastases can be manipulated for
the benefit of the patient is well established. It is now time to
go on to a new set of research questions and to determine
how we can improve on these important initial advances.654 I.C. HENDERSON
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